Dong-A Pharmaceutical has launched OZEX OPHTHALMIC SOLUTION 0.3 (active ingredient: Tosufloxacin
tosilate), a quinolone antibiotic eye drop agent.



OZEX OPHTHALMIC SOLUTION, a new quinolone antibiotic eye drop agent developed by Toyama Chemical, a
subsidiary of Fujifilm Holdings Corporation, is a potent, broad-spectrum antibiotic that effectively battles a wide
range of eye infection-causing bacteria. Most notably, its safety and efficacy for young children (including
infants and newborn babies) have been substantiated, which is a first for a product of this kind.



The domestic quinolone antibiotic eye drop market is roughly 25 billion KRW and is growing at about 12 percent
every year thanks to rising demand not only due to such need to treat external ocular diseases as
conjunctivitis and keratitis but also because of increasing demand for LASIK and LASEK surgeries.



“We are planning to further prove its efficacy and safety through post-marketing surveillance (PMS) and a
range of clinical trials in Korea. Even though it is an original (non-generic) agent, the price is lower than those
of competitors’ products, reducing costs to patients,” says the marketer of OZEX OPHTHALMIC SOLUTION,
adding, “OZEX will be a great help for external ocular diseases and for asepsis before and after surgery.”